GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neurotech International Ltd (ASX:NTI) » Definitions » Cash Ratio

Neurotech International (ASX:NTI) Cash Ratio : 16.23 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Neurotech International Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Neurotech International's Cash Ratio for the quarter that ended in Dec. 2023 was 16.23.

Neurotech International has a Cash Ratio of 16.23. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Neurotech International's Cash Ratio or its related term are showing as below:

ASX:NTI' s Cash Ratio Range Over the Past 10 Years
Min: 0.02   Med: 5.64   Max: 22.07
Current: 16.23

During the past 7 years, Neurotech International's highest Cash Ratio was 22.07. The lowest was 0.02. And the median was 5.64.

ASX:NTI's Cash Ratio is ranked better than
97.51% of 842 companies
in the Medical Devices & Instruments industry
Industry Median: 1.23 vs ASX:NTI: 16.23

Neurotech International Cash Ratio Historical Data

The historical data trend for Neurotech International's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurotech International Cash Ratio Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Ratio
Get a 7-Day Free Trial 1.34 0.02 13.83 3.20 3.73

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.20 3.20 22.07 3.73 16.23

Competitive Comparison of Neurotech International's Cash Ratio

For the Medical Devices subindustry, Neurotech International's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurotech International's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neurotech International's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Neurotech International's Cash Ratio falls into.



Neurotech International Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Neurotech International's Cash Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash Ratio (A: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.026/1.347
=3.73

Neurotech International's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=4.479/0.276
=16.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurotech International  (ASX:NTI) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Neurotech International Cash Ratio Related Terms

Thank you for viewing the detailed overview of Neurotech International's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurotech International (ASX:NTI) Business Description

Traded in Other Exchanges
N/A
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Neurotech International Ltd is a medical device and solutions company. It researches, designs, markets, and produces wearable neurotechnology devices to assist with neurological conditions such as autism. Geographically, all the business activities of the firm function through the region of Australia. It operates in one segment named Medical Device Development and Distribution.

Neurotech International (ASX:NTI) Headlines

From GuruFocus

How to Capitalize on the Bakken Oil Boom

By Vitaliy Katsenelson Vitaliy Katsenelson 11-09-2013

13 Stocks With Dividend Yields Over 10%

By Dividend Dividend 11-12-2014

20 Stocks with Yields over 10% and Highest Buy Ratings

By Dividend Dividend 01-17-2013

9 Stocks With Yields Over 10% And Buy Or Better Rating

By Dividend Dividend 08-17-2013